U.S. markets open in 8 hours 10 minutes
  • S&P Futures

    3,902.75
    -1.00 (-0.03%)
     
  • Dow Futures

    31,437.00
    +16.00 (+0.05%)
     
  • Nasdaq Futures

    12,034.50
    -6.00 (-0.05%)
     
  • Russell 2000 Futures

    1,771.90
    +2.10 (+0.12%)
     
  • Crude Oil

    110.82
    +1.25 (+1.14%)
     
  • Gold

    1,827.00
    +2.20 (+0.12%)
     
  • Silver

    21.18
    +0.01 (+0.06%)
     
  • EUR/USD

    1.0580
    -0.0007 (-0.06%)
     
  • 10-Yr Bond

    3.1940
    0.0000 (0.00%)
     
  • Vix

    26.95
    -0.28 (-1.03%)
     
  • GBP/USD

    1.2272
    +0.0002 (+0.02%)
     
  • USD/JPY

    135.2800
    -0.1660 (-0.12%)
     
  • BTC-USD

    20,762.21
    -418.10 (-1.97%)
     
  • CMC Crypto 200

    451.39
    -10.40 (-2.25%)
     
  • FTSE 100

    7,258.32
    +49.51 (+0.69%)
     
  • Nikkei 225

    26,941.99
    +70.72 (+0.26%)
     

UPDATE 1-U.S. FDA declines to authorize Verrica's viral skin disease treatment

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

(Adds more details from statement, background)

May 24 (Reuters) - The U.S. Food and Drug Administration (FDA) declined to approve Verrica Pharmaceuticals Inc's drug for the treatment of a viral skin disease known as molluscum contagiosum, the company said on Tuesday.

The disease is caused by a pox virus and leads to skin-toned to pink-colored lesions that can cause pain, inflammation, itching and bacterial infection. While the lesions usually go away within a year without scarring, some cases could take a lot more time.

There are currently no approved treatments in the United States for the condition.

The FDA denied approval for Verrica's drug VP-102 due to deficiencies identified at Sterling Pharmaceuticals Services, a contract manufacturer that produces Verrica's bulk solution drug product, during a general re-inspection, which resulted in an Official Action Indicated (OAI) status.

An OAI is the FDA's most serious category of violation, and regulatory experts say it could lead to a prohibition on the sale of drugs from a facility if not addressed.

Verrica said it had been told that internal policy is preventing the health regulator from "communicating the label and approving the NDA (New Drug Application)" when a contract manufacturer is placed on OAI status.

None of the issues identified by the FDA during its re-inspection were specific to the manufacturing of VP-102, Verrica said in its statement.

The health regulator had declined Verrica's marketing application for the drug last year, citing general quality issues at one of the company's third-party manufacturing facilities. (https://bit.ly/3lc4lAn)

(Reporting by Bhanvi Satija, Amruta Khandekar and Sneha Bhowmik; additional reporting by Juby Babu in Bengaluru; Editing by Subhranshu Sahu)